Supply Chain | August 31, 2024
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
